Do Intravaginal Devices Reduce Urinary Incontinence in Female Runners?

November 16, 2023 updated by: Dr. Linda McLean, University of Ottawa

Do Intravaginal Devices Reduce or Eliminate Exercise Induced Urinary Incontinence in Female Runners?

More than one in five females experience the embarrassment and shame of urine leakage while exercising and this urinary incontinence (UI) is a substantial barrier to exercise. As many as one in three females with UI report that they limit their physical activity due to incontinence: 11.6% by not exercising at all, 11.3% by exercising less and 12.4% by changing the type of exercise they perform. It is imperative to look for alternatives to manage this condition, as it is a key reason why females abandon the very physical exercise that is necessary to maintain or improve their physical and mental health and their quality of life.

While there is Grade A evidence for pelvic floor muscle training and some evidence for intravaginal pessaries to reduce symptoms of UI in general female populations, no study has evaluated the impact of conservative interventions specifically on UI experienced predominantly during running.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Urinary incontinence (UI) is a serious public health concern, imposing a significant financial burden. In Canada the direct and indirect health costs associated with UI total over 3.6 billion annually and no estimates of disease burden take into account deconditioning that results from withdrawal from physical activity nor effects on mental health or quality of life. Although the primary risk factor for UI is pregnancy and vaginal delivery, it was recently reported that between 20% and 40% of nulliparous females report urine leakage when they engage in physical activity.

Urinary continence is maintained as long as urethral closure pressure remains higher than bladder pressure. This is accomplished through a complex combination of mechanisms, including smooth and striated urethral sphincter muscle action, urethral venous engorgement and mucous secretions within the urethra, and the proper transfer of loads to the urethra, which depends on adequate bladder neck and urethral connective tissue support as well as pelvic floor muscle (PFM) action. The associations among physical activity, pelvic floor morphology and function, and UI are not clear. A recent systematic review retrieved 18 mainly small studies investigating the association between physical activity and pelvic floor dysfunction. Exercise at mild to moderate intensity appears to be protective, decreasing both the odds and the risk of experiencing urinary incontinence. However, females who engage in high-impact activities such as running are more likely to report UI during exercise than those who engage in mild or moderate intensity exercise, thus chronic and repetitive loading of the pelvic floor may have negative consequences.

While there is Grade A evidence for pelvic floor muscle training and some evidence for intravaginal pessaries to reduce symptoms of UI in general female populations, no study has investigated about interventions specific to running-induced UI.

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Canada
    • Ontario
      • Ottawa, Ontario, Canada, K1S 1S2
        • Recruiting
        • McLean Function Measurement Lab
        • Contact:
          • Anne-Marie MacDonald, MSc
          • Phone Number: 4102 (613) 562-5800
          • Email: mfmlab@uottawa.ca
        • Contact:
        • Principal Investigator:
          • Linda McLean, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Cis-females aged 18 years and over who run at least 5 km in under 50 minutes (minimum speed of 6 km/h to ensure high impact), at least twice per week (to ensure adequate frequency), and who have done so for at least one year (to ensure adequate duration of exposure);
  • Who regularly (≥ 1 per week) experience urine leakage while running and who report ≤1 urine leakage episode per month not associated with exercise;

Exclusion Criteria:

  • Any risk factors related to exercise;
  • If they report any pain or musculoskeletal injury at the time of the screening;
  • History of urogenital surgery;
  • Symptoms of the female athlete triad;
  • Dyspareunia to the extent that they cannot undergo a regular gynaecologic examination;
  • Have a known neurologic disorder (e.g. stroke, multiple sclerosis);
  • Pregnancy or partum within the previous year;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pessary Intervention

Participants randomized to this group will receive an Uresta Incontinence Pessary to use each time they run over a 12-week period. They will be instructed to use the pessary only while running and remove it and wash it with soap and water when the training is over.

Uresta is a reusable and removable device made of hypoallergenic medical-grade resin that is inserted into the vagina to provide mechanical support. It comes with a starter kit with 3 different sizes which work for over 80% of women. Participants will be instructed on how to test the 3 sizes to find out which one is right for them.
Device: Pessary Intervention
Participants will receive a 3-size fitting kit and will fit the appropriate size based on manufacturer instruction. Once the size is verified, the participants will be asked to use the pessary while running over a 12-week period.
Experimental: Tampon Intervention
Participants randomized to this group will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 12-week period. The tampon should be used only while running and removed and discarded when the training is over.
Device: Tampon Intervention
Participants will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 12-week period.
No Intervention: Control Group
Participants randomized to this group won't receive any intervention and will be asked to continue their running training as usual for 12-weeks. They will also be instructed to not begin any treatment for urinary incontinence until their reassessment. After 12-weeks, they will be reassessed and will be offered the opportunity to receive a pessary if they desire so.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of training sessions during which urine leakage occurred
Time Frame: 10-12 weeks
Participants will be asked to complete a bladder diary recording leakage experiences during each running session over a two-week period before their first lab assessment and over a two-week period again beginning in the tenth week after starting the protocol. They will receive daily reminders to fill it out.
10-12 weeks
Brisk walking and Running lower Urinary Tract Symptoms Questionnaire (BRUTS) score
Time Frame: 12 weeks; follow-up at 4, 12 and 24 weeks later.

The Brisk walking and Running Lower Urinary Tract Symptoms Questionnaire evaluates the symptoms and management strategies associated with urinary urgency and urinary incontinence that occurs during brisk walking, jogging, and running. Participants will be asked to complete it before coming for their first lab assessment and after 12-weeks. Also, a follow-up will be conducted upon finishing the intervention, and participants will be invited to complete the questionnaire again at 4, 12 and 24 weeks later.

The questionnaire has 4 domains: (1) about urgency symptoms, (2) about urgency urinary incontinence (UUI), (3) about stress urinary incontinence (SUI) and (4) about symptoms management. Scores are all 0-100 and higher scores mean a worse outcome with regards to the impact of lower urinary tract symptoms. The total score is still out of 100 (Urgency + UUI + SUI + Management / 4).
12 weeks; follow-up at 4, 12 and 24 weeks later.
Patient's global perception of improvement
Time Frame: 12 weeks; follow-up at 4, 12 and 24 weeks later.
Participants will be asked to rate their overall impression of how much the symptoms improved with the intervention on a scale of 0 to 100 after 12-weeks. Also, a follow-up will be conducted upon finishing the intervention, and, if they are still using the intervention, participants will be invited to rate their overall impression again at 4, 12 and 24 weeks later. Higher scores mean a better outcome = more improvement.
12 weeks; follow-up at 4, 12 and 24 weeks later.
Patient's global satisfaction with treatment
Time Frame: 12 weeks; follow-up at 4, 12 and 24 weeks later.
Participants will be asked to rate their satisfaction with the intervention on a scale of 0 to 100 after 12-weeks. Also, a follow-up will be conducted upon finishing the intervention, and, if they are still using the intervention, participants will be invited to rate their satisfaction again at 4, 12 and 24 weeks later. Higher scores mean a better outcome = more satisfied.
12 weeks; follow-up at 4, 12 and 24 weeks later.
International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules (ICIQ-FLUTS)
Time Frame: 12 weeks; follow-up at 4, 12 and 24 weeks later.

The ICIQ-FLUTS is a questionnaire for evaluating female lower urinary tract symptoms and impact on quality of life in research and clinical practice, with validity, reliability and responsiveness established with rigour in several data sets. It has a total of 12 questions; four questions on filling symptoms, three on voiding symptoms and five questions on urinary incontinence symptoms. The overall score ranges from 0-48, where all subscales scores are added. Higher scores indicate greater impact of individual symptoms for the patient.

Participants will be asked to complete it before coming for their first lab assessment and after 12-weeks. Also, a follow-up will be conducted upon finishing the intervention, and participants will be invited to complete the questionnaire again at 4, 12 and 24 weeks later.
12 weeks; follow-up at 4, 12 and 24 weeks later.
Intervention questionnaire
Time Frame: 12 weeks; follow-up at 4, 12 and 24 weeks later.
A custom questionnaire with 20 questions was developed to collect information regarding participant's experience running with the intervention (tampon or pessary). The questions addresses the frequency of intervention use, ease of insertion and removal, comfort level while using the device, adverse events (bleeding, vaginal discharge, pain), overall satisfaction, and the extent of urine leakage with the dispositive. Each question is rated on a scale form 0 to 100, with higher scores indicating a greater experience with the intervention. Participants randomized to the intervention groups will be asked to complete the questionnaire related to their assigned intervention after 12-weeks. Additionally, a follow-up will be conducted upon completing the intervention, and participants will be invited to complete the questionnaire again at 4, 12 and 24 weeks later.
12 weeks; follow-up at 4, 12 and 24 weeks later.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pad weight gain
Time Frame: 12 weeks
Participants will be provided with a pre-weighed pad to attach to their underwear and wear it while running for 30 minutes on the treadmill. Once they finish running, the pad will be weighted again to record urine leakage. This will be done at the baseline and after 12-weeks.
12 weeks
Adherence to each intervention
Time Frame: Once a week during the 12 weeks of the study
Adherence to the interventions will be logged through weekly e-mail contact, followed up with telephone contact if there is no response to the e-mail.
Once a week during the 12 weeks of the study
Adverse events
Time Frame: Once a week during the 12 weeks of the study
Adverse events (bleeding, vaginal discharge, pain, etc.) will be assessed through weekly e-mail contact, followed up with telephone contact if there is no response to the e-mail.
Once a week during the 12 weeks of the study
Changes in bladder neck height
Time Frame: 12 weeks
Changes in bladder neck height will be assessed by Ultrasound imaging at baseline and after 12-weeks. The images will be recorded before and after a 30-minute running protocol on a treadmill.
12 weeks
Changes in levator hiatus area
Time Frame: 12 weeks
Changes in levator hiatus area will be assessed by Ultrasound imaging at baseline and after 12-weeks. The images will be recorded before and after a 30-minute running protocol on a treadmill.
12 weeks
Changes in levator plate lenght
Time Frame: 12 weeks
Changes in levator plate lenght will be assessed by Ultrasound imaging at baseline and after 12-weeks. The images will be recorded before and after a 30-minute running protocol on a treadmill.
12 weeks
Changes in pelvic floor muscle strength
Time Frame: 12 weeks
Changes in pelvic floor muscle strength will be assessed at baseline and after 12-weeks using an intravaginal dynamometer. The measures will be recorded before and after a 30-minute running protocol on a treadmill.
12 weeks
Changes in pelvic floor muscle stiffness
Time Frame: 12 weeks
Changes in pelvic floor muscle stiffness will be assessed at baseline and after 12-weeks using an intravaginal dynamometer. The measures will be recorded before and after a 30-minute running protocol on a treadmill.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Ottawa

Investigators

  • Principal Investigator: Linda McLean, University of Ottawa

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 14, 2023

Primary Completion (Estimated)

February 1, 2025

Study Completion (Estimated)

February 1, 2025

Study Registration Dates

First Submitted

January 14, 2023

First Submitted That Met QC Criteria

March 6, 2023

First Posted (Actual)

March 17, 2023

Study Record Updates

Last Update Posted (Actual)

November 18, 2023

Last Update Submitted That Met QC Criteria

November 16, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H-06-22-8219

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Spreadsheets will be provided by email upon request and based on the planned use of the data.

IPD Sharing Time Frame

Data will be available for 10 years after the publication of the study results.

IPD Sharing Access Criteria

Planned use of data for systematic review or meta-analysis.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urinary Incontinence

Clinical Trials on Pessary Intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe